Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
22.29
+0.63 (2.91%)
At close: Jun 26, 2026, 4:00 PM EDT
22.57
+0.28 (1.26%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Monte Rosa Therapeutics stock have an average target of 32.5, with a low estimate of 29 and a high estimate of 37. The average target predicts an increase of 45.81% from the current stock price of 22.29.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 11, 2026.
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $30 → $31 | Buy | Reiterates | $30 → $31 | +39.08% | May 11, 2026 |
| Wedbush | Wedbush | Buy Maintains $37 | Buy | Maintains | $37 | +65.99% | May 8, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $37 | Buy | Reiterates | $37 | +65.99% | May 8, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 7, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
Financial Forecast
Revenue This Year
44.48M
from 123.67M
Decreased by -64.04%
Revenue Next Year
58.17M
from 44.48M
Increased by 30.79%
EPS This Year
-1.59
from -0.46
EPS Next Year
-1.81
from -1.59
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 191.0M | 286.0M | |
| Avg | 44.5M | 58.2M | |
| Low | 4.0M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 54.4% | 543.0% | |
| Avg | -64.0% | 30.8% | |
| Low | -96.8% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.24 | 0.36 | |
| Avg | -1.59 | -1.81 | |
| Low | -2.24 | -2.91 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.